Portfolio

We have a broad portfolio covering a wide range of therapeutic areas, and across modalities, from small molecules to cell therapy. Many have already attracted investments from top tier investors such as BB Pureos Bioventures, NEA, Syncona, Sofinnova, the Novartis Venture Fund, Biomedinvest, Boehringer Ingelheim Venture Fund, and others.

Financed: $13M raised

New target/core pathway for fibrosis. Treatment of late stage fibrosis, related cancers. Initially liver.

Financed: $37.5 raised

Antibody platform re-focusing IL-2 to CTLs to fuel anti-cancer immunity.

Incubating

Developing novel inflammasome inhibitors.

Incubating

Tag cell populations for removal or shielding. Better, safer safe bone marrow transplants and stem cell replacement.

Incubating

Gene logic circuits. In-vivo multifactorial identification and killing of cancer cells.

Incubating

Bacterial mixes as microbiome therapeutics in IBD and oncology based on mixed-culture technology.

Financed: $41.5M raised

Glycomimetic platform for removing auto-antibodies in autoimmune neuropathies.

Incubating

Novel targets that mediate endocannabinoid efficacy. Treatments for stress, anxiety etc.

Incubating

First-in-class therapeutics to stop neurodegenerative diseases with a selective small molecule approach.

Financed: $42M raised

Intracellular delivery of therapeutic payloads using bacteria, exploiting bacterial tumor targeting.

Financed

Functional ID of (neo)antigens for cancer, immunological and infectious diseases.

Financed: $16.5M raised

Cancer drug resistance platform to develop small molecules addressing non mutational mechanisms of therapy evasion.

Financed: $18.5M raised

mRNA platform for local regenerative medicine-based therapeutics.

Application cycle is now open!

Last deadline for 2020 is October 25